A Prospective Observational Study for Evaluating CGVHD (GITMO-GVCrOSy)

A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria

Prospective, observational, multicentre, spontaneous, non-interventional study This study will evaluate all consecutive patients who develop chronic graft-versus-host disease, reported by the Italian GITMO centers according to a standardized Web platform for real-time, onsite data collection. The platform for data collection will be based on a software prototype developed by the Clinica di Ematologia di Ancona Transplant Center for the management of patients with chronic graft-versus-host disease. This software has been integrated with algorithms that automatically determine: severity of chronic graft-versus-host disease and overall response according to the 2015 NIH consensus criteria.

Study Overview

• Status: Completed
• Conditions: Chronic Graft-Versus-Host Disease

Detailed Description

Chronic Graft-versus-Host Disease represents the first cause of transplant-related mortality and reduced quality of life after transplant (HSCT). The epidemiology of Chronic Graft-versus-Host Disease is largely unknown; moreover, diagnosis of Chronic Graft-versus-Host Disease can be easily missed because its onset is often late in the post-transplant period, requires specific follow up, and general practitioners are usually not familiar with this entity. Successful treatment of Chronic Graft-versus-Host Disease represents an unmet clinical need in the field of allogeneic transplantation. Steroids are standard treatment, but up to 60% of the patients will require second-line treatment but there is no standard second-line treatment for Chronic Graft-versus-Host Disease steroid refractory. To help standardise the management Chronic Graft-versus-Host Disease, the NIH Consortium proposed consensus definitions for diagnosis, scoring and response criteria in 2006 revised in 2015 which offers a shared framework to study this rare disease. These criteria are not yet validated and thus not suitable for clinical trials.

This study is prospective, observational, multicentre, spontaneous, non-interventional study that will evaluate all consecutive patients who develop chronic graft-versus-host disease, reported by the Italian GITMO centers according to a standardized Web platform for real-time, on-site data collection. The platform for data collection will be based on a software prototype developed by the Ancona Transplant Center for the management of patients with Chronic Graft-versus-Host Disease. This software has been integrated with algorithms that automatically determine: severity of Chronic Graft-versus-Host Disease and overall response by the 2015 NIH consensus criteria. Historical controls to compare Chronic Graft-versus-Host Disease incidence, toxicities, response rate and hard outcomes will be used.

The aim of this project is to evaluate prospectively the long-term effectiveness of different therapies by the hard outcome "failure free survival" commonly considered the most reliable one. The failure free survival is the result of a number of factors that influence the treatment failure and has been shown a reliable predictor of long-term survival. Main cause of failure is the change in immunosuppressive treatment although recurrent disease, treatment toxicity and mortality from Chronic Graft-versus-Host Disease (or other infectious complications) also contribute to failure free survival. Second, we aim to evaluate the prognostic ability of the latest NIH response criteria to predict main hard survival outcomes and to assess their suitability as a tool for decision-making that ultimately leads to treatment changes. Finally, we aim to evaluate the feasibility of the use of an electronic tool for data collection in daily clinical practice.

• Study Type: Observational
• Enrollment (Actual): 248

Contacts and Locations

Study Locations

• Italy
  • Alessandria, Italy
    • Azienda Ospedaliera SS Antonio e Biagio
  • Ancona, Italy
    • Azienda Ospedaliero-Universitaria Ospedali Riuniti
  • Bari, Italy
    • Policlinico di Bari-Ematologia con trapianti
  • Bergamo, Italy
    • Divisione di Ematologia - Ospedali Papa Giovanni XXIII
  • Bologna, Italy
    • Ospedale San Orsola
  • Bolzano, Italy
    • Ospedale Regionale Generale- Divisione Ematologia
  • Brescia, Italy
    • AO Spedali Civili di Brescia- USD - TMO Adulti
  • Catania, Italy
    • Ospedale Ferrarotto - Ematologia
  • Cuneo, Italy
    • S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle
  • Firenze, Italy
    • Cattedra di Ematologia - Azienda Ospedaliera di Careggi
  • Genova, Italy
    • Ospedale Gaslini
  • Lecce, Italy
    • Osp. Card. Panico
  • Milano, Italy
    • Ospedale San Raffaele
  • Milano, Italy
    • Ospedale Maggiore - Policlinico
  • Monza, Italy
    • CTMO Fond MBBM Clinica pediatrica
  • Napoli, Italy
    • Uoc Sit Tmo
  • Parma, Italy
    • Azienda Ospedaliera Universitaria di Parma
  • Piacenza, Italy
    • Ospedale G. Da Saliceto di Piacenza
  • Pisa, Italy
    • Azienda Ospedaliero Universitaria Pisana
  • Reggio Calabria, Italy
    • Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli
  • Reggio Emilia, Italy
    • Arciospedale S. M. Novella
  • Roma, Italy
    • Cattedra di Ematologia - Policlinico Umberto I
  • Torino, Italy
    • Ospedale Regina Margherita
  • Torino, Italy
    • A.O.U. Città della Salute e della Scienza
  • Udine, Italy
    • A.O. Santa Maria della Misericordia
  • Verona, Italy
    • Policlinico GB Rossi
  • Vicenza, Italy
    • Ospedale S. Bortolo-Divisione Ematologia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All consecutive patients undergoing sllogenic stem cell transplant for any underlyng disease who develop chronic graft-versus-host disease (cGVHD)

Description

Inclusion Criteria:

• Any age
• All patients who develop cGVHD (any grade) by the NIH criteria after allogeneic transplantation
• Written and signed informed consent

Exclusion Criteria:

• Absence of informed consent

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients with cGVHD; All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Failure free survival (FFS)	To estimate the failure free survival measured from the start of 1st line immunosuppressive treatment for cGVHD, defined as the probability of survival free of any of the following events: cGVHD progression, need of a new immunosuppressive treatment, need of treatment dose escalation, relapse of the underlying hematological disease, severe (CTCAE grade 3-4) toxicity.	Measured from the start of 1st line immunosuppressive treatment for cGVHD until the date of first documented progression or date of death from any cause whichever came first, assessed up to 1 years from transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response rate (RR)	Global and organ-specific response rate (RR), evaluated 3 and 6 months after starting systemic treatment, by the 2015 NIH criteria	3 and 6 months
Incidence and grade of cGVHD	Incidence and grade of cGVHD, by the 2015 NIH criteria at 1 year after Hematopoietic stem cell transplantation (HSCT)	at 1 year from transplant
relapse	Cumulative incidence of relapse of underlying haematological malignancy	1 year from transplant
non-relapse mortality	Cumulative incidence of non-relapse mortality (NRM), defined as any death not due to disease relapse or progression	1 year from transplant
treatment change	Cumulative incidence of treatment change, measured from the start of first-line and subsequent treatment lines	measured from the start of first-line and subsequent treatment lines for 1 year
Successful withdrawal of immunosuppressive treatment	Cumulative incidence of successful withdrawal of immunosuppressive treatment, measured from the start of first-line and subsequent treatment lines.	Measured from the start of firs-tline and subsequent treatment lines for 1 year
Overall Survival	Overall Survival, measured from cGVHD diagnosis.	measured from cGVHD diagnosis until 1 year
Severe Adverse Events (SAE) and Toxicities	Incidence of Severe Adverse Events (SAE), toxicities (by the Common Terminology Criteria for Adverse Events - CTCAE), infections during treatments.	Measured from first treatment for cGVHD until 1 year

Collaborators and Investigators

• Sponsor: Gruppo Italiano Trapianto di Midollo Osseo
• Investigators: Principal Investigator: Attilio Olivieri, MD, AOU Ospedali Riuniti di Ancona

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 1, 2017
• Primary Completion (ACTUAL): November 22, 2022
• Study Completion (ACTUAL): November 22, 2022

Study Registration Dates

• First Submitted: December 6, 2016
• First Submitted That Met QC Criteria: December 13, 2016
• First Posted (ESTIMATE): December 14, 2016

Study Record Updates

• Last Update Posted (ACTUAL): November 25, 2022
• Last Update Submitted That Met QC Criteria: November 23, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: GITMO; chronic graft-versus-host disease cGVHD; Hematopoietic stem cell transplantation HSCT; NIH consensus criteria
• Additional Relevant MeSH Terms: Immune System Diseases; Graft vs Host Disease
• Other Study ID Numbers: GITMO-GVCrOSy